First Phase III Results Keep Pfizer's Abrocitinib Among JAK Leaders In Atopic Dermatitis
Pfizer follows Lilly as the second company to report positive top-line Phase III results in AD for a JAK inhibitor. Safety is a key concern for the class, but Pfizer did not provide any details about abrocitinib's side effects.
You may also be interested in...
A second Phase III JADE study showed statistically significant skin clearance and reduced pruritus in atopic dermatitis, although safety is harder to evaluate for now. A filing planned for 2020 will include results from a cross-study comparison evaluating abrocitinib versus Dupixent.
Trulicity, Taltz grew in the first quarter, but below analyst consensus estimates. Company points to price decreases as holding down growth.
Pfizer will be active in business development, management said, but with a focus on building out the pipeline with bolt-on deals in the range of a "few billion." Gene therapy remains one area of interest.